Exelixis, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Exelixis, Inc. - overview
Location
South San Francisco, CA, US
Primary Industry
Biotechnology
About
Exelixis, Inc. is a biotechnology company focused on developing and commercializing innovative cancer therapies, emphasizing treatment for complex cancers through advanced biotherapeutics and small molecules. Exelixis, Inc. specializes in the development of treatments for cancer, particularly targeting advanced neuroendocrine tumors and squamous cell carcinoma of the head and neck.
Founded in South San Francisco, US, the company has undergone strategic changes aligned with its focus on oncology. The company went public on April 11, 2000, raising USD 118. 3 mn in its IPO by selling 9. 1 million shares at USD 13 per share.
The current CEO is Michael Morrissey. Exelixis, Inc. specializes in the development and commercialization of innovative cancer therapies, with a primary focus on advanced neuroendocrine tumors and squamous cell carcinoma of the head and neck. The company’s flagship product, cabozantinib, inhibits multiple signaling pathways involved in tumor growth and is available for patients who have previously undergone treatments for advanced neuroendocrine tumors.
The company is advancing a diverse pipeline, including bispecific antibodies and antibody-drug conjugates, targeting various cancer types, distributing primarily in the United States and European markets through healthcare providers, hospitals, and specialty pharmacies. For the fiscal year 2024, Exelixis reported a revenue of USD 2. 17 bn, with an EBITDA of USD 633. 42 mn.
Revenue is primarily generated through the sale of cabozantinib, marketed as CABOMETYX, with transactions facilitated through healthcare providers and specialty pharmacies, ensuring medications reach the appropriate patient demographics. Exelixis plans to expand its product portfolio by developing new therapies aimed at various cancer types, with specific timelines for product launches to be determined. The company is also targeting entry into new international markets to broaden its reach. The funding raised in its IPO in 2000 will support these initiatives, facilitating research and development efforts aimed at advancing its therapeutic pipeline.
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Website
www.exelixis.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Exelixis, Inc. - timeline of key events
Exelixis, Inc. - financials
| Fiscal Year Ended | Dec 30, 2011 | Dec 28, 2012 | Dec 27, 2013 | Dec 27, 2014 | Jan 02, 2015 | Dec 30, 2016 | Dec 29, 2017 | Dec 28, 2018 | Dec 28, 2019 | Jan 03, 2020 | Jan 01, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 289,636,000 | 47,450,000 | 31,338,000 | - | 25,111,000 | 191,454,000 | 452,477,000 | 853,826,000 | - | 967,775,000 | 987,538,000 | 1,401,243,000 | - | - | - |
| % Revenue Growth (YoY) | - | (83.6%) | (34.0%) | - | - | - | - | 88.7% | - | - | - | - | - | - | - |
| EBITDA (USD) | 96,357,000 | (116,719,000) | (197,585,000) | - | (222,067,000) | (18,690,000) | 167,279,000 | 446,624,000 | - | 377,818,000 | 119,201,000 | 222,359,000 | - | - | - |
| Operating Income (USD) | 89,535,000 | (122,436,000) | (200,732,000) | - | (224,458,000) | (28,124,000) | 165,910,000 | 438,855,000 | - | 369,470,000 | 110,060,000 | 201,484,000 | - | - | - |
| Operating Margin | 30.9% | (258.0%) | (640.5%) | - | (893.9%) | (14.7%) | 36.7% | 51.4% | - | 38.2% | 11.1% | 14.4% | - | - | - |
| % EBITDA Margin | 33.3% | (246.0%) | (630.5%) | - | (884.3%) | (9.8%) | 37.0% | 52.3% | - | 39.0% | 12.1% | 15.9% | - | - | - |
| NET Income (USD) | 75,697,000 | (147,645,000) | (244,760,000) | - | (268,542,000) | (70,222,000) | 154,227,000 | 690,070,000 | - | 321,012,000 | 111,781,000 | 182,282,000 | - | - | - |
| % Net Margin | 26.1% | (311.2%) | (781.0%) | - | (1069.4%) | (36.7%) | 34.1% | 80.8% | - | 33.2% | 11.3% | 13.0% | - | - | - |
Exelixis, Inc. - employee data
Exelixis, Inc. - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Member, Board of Directors | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.